EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Multiomic Landscape Uncovers TRMT112 as a Central Driver of HPV‐Positive Head and Neck Squamous Cell Carcinoma

Tongnan Yin, Qian Guo, Zhenwei Wen, Yikun Guo, Chenwen Li, Zhongyu Qu

Human Mutation · 2025-01 · 2025 (1)

DOI: 10.1155/humu/5308441 ↗
AbstractBibliografische Angaben

Abstract

Head and neck squamous cell carcinoma (HNSCC) ranks second among men and sixth globally, with a notable increase in HPV‐associated cases. However, the molecular underpinnings and immune landscape of HPV+ HNSCC remain incompletely understood. In this study, we first retrieved and harmonized single‐cell RNA sequencing (RNA‐Seq), bulk RNA‐Seq, and spatial transcriptomic profiles from public repositories. We then applied high‐dimensional weighted gene coexpression network analysis (hdWGCNA) and gene nonnegative matrix factorization (GeneNMF) to dissect HPV+ epithelial subpopulations, their extracellular matrix (ECM)–interacting ligand programs, and CXCL/complement immune circuits. Furthermore, we mapped the spatial niches of malignant and immune cells and constructed a consensus prognostic index using 101 machine learning algorithms. Our findings revealed transcriptionally distinct HPV+ epithelial clusters that activate viral oncogenesis, inflammatory pathways, and ECM‐sensing pathways. These cells communicate with stromal and immune compartments via CXCL axes and complement cascades, yet they are spatially segregated from lymphocytes. A high‐risk signature, identified as HPV‐related risk genes including TRMT112, stratified the TCGA‐HNSC and GSE65858 cohorts into patients with markedly worse 1‐, 2‐, and 3‐year survival rates (ROC–AUC 0.934, 0.968, and 0.973) and poor responses to immunotherapy. Notably, TRMT112 expression inversely correlated with cytotoxic T‐cell infiltration, mechanistically linking it to the formation of “cold” tumors. Our integrative analysis defines HPV‐driven epithelial subpopulations whose TRMT112‐enriched, immune‐excluded microenvironment contributes to therapeutic resistance, thus providing robust prognostic biomarkers and actionable targets for precision immunotherapy in HPV+ HNSCC.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →